Quince Therapeutics filed an amendment to its certificate of incorporation to implement a 1-for-20 reverse stock split effective June 29, 2026. The amended charter failed to include a redelivery provision, which could be material for investors.
Quince Therapeutics filed an amendment to its certificate of incorporation to implement a 1-for-20 reverse stock split effective June 29, 2026. The amended charter failed to include a redelivery provision, which could be material for investors.